99mTc-ADAPT6-based HER2 Imaging in Breast Cancer

Condition:   Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   KTH Royal Institute of Technology;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   KTH Royal Institute of Technology;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We examined the following three conditions: DMEM high glucose which contained 4.5 mg/ml glucose, independent of serum, DMEM low glucose which contained 1.0 mg/ml glucose, independent of serum. And, DMEM no glucose which contained 0.0 mg/ml glucose, independent of serum. DMEM is referred to as glucose “free,” however some glucose was actually present due to the FBS. The glucose concentration in the FBS used was 1.04 mg/ml. We calculate 0.0937 mg/ml glucose was present in the media under all conditions due to the addition of serum. Quantification of ROS Levels ROS are widely evaluated in tissue culture using di...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Contrary to popular belief, we demonstrate that DOTA-PRIT can be successfully adapted to an internalizing antigen-antibody system such as HER2, with sufficient TIs and absorbed tumor doses to achieve a high probability of cures of established human breast cancer xenografts while sparing critical organs of significant radiotoxicity.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: The radiolabeled HER2-selective inhibitor 125/131I-IBA-CP is a promising probe for in vivo detection of HER2-positive tumors.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Source Type: research
Increased expression of the human epidermal growth factor receptor (HER) protein family are targets in breast cancer for imaging and therapy. Imaging modalities targeting HER2 and HER3 can diagnose breast cancer with a specific, biologically relevant target. Repeat biopsies do not address heterogeneity intratumorally or between primary disease and metastasis. HER2- and HER3-targeted PET is an important tool to diagnose disease in breast cancer and evaluate response to targeted therapies. PET and single photon emission computed tomography with radiolabeled biomolecules can be used to detect and quantify specific targets, co...
Source: PET Clinics - Category: Radiology Authors: Source Type: research
Condition:   Breast Cancer Intervention:   Biological: 99mTc-ABH2 Sponsor:   Peking Union Medical College Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Research | Russia Health | SPECT